Áttétes emlőrák: vizsgálatok itt: Izrael
16 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Where
- Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 1132 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00 - 2/3. fázisTaking peopleRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Where
- Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 650 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00 - 3. fázisTaking peopleA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Where
- Beersheba, Haifa, Jerusalem, Ramat Gan
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00 - 3. fázisTaking peopleSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Where
- Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 788 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00 - 3. fázisTaking peopleEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Where
- Afula, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Rehovot, Tel Aviv, Tel HaShomer
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- LeonaBio
See details and how to joinNCT05696626 · EU 2023-503708-10-00 - No phaseTaking peopleOrgan Culture for Endocrine Resistant Next Line: A Treatment Selection Study in Metastatic Breast Cancer
- Where
- Tel Aviv
- Életkor
- 18 év and over
- People
- 39
- Run by
- Tel-Aviv Sourasky Medical Center
See details and how to joinNCT07895160 - 1/2. fázisTaking peopleStudy of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- Where
- Haifa, Petah Tikva, Ramat Gan
- Életkor
- 18 év and over
- People
- 181 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06686394 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Where
- Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00 - 3. fázisTaking peopleA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Where
- Haifa, Jerusalem, Petah Tikva, Ramat Gan
- Életkor
- 18 év and over
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00 - 3. fázisTaking peoplePalazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Where
- Ashdod, Jerusalem, Kfar Saba, Petah Tikva
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00 - 3. fázisTaking peopleStereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
- Where
- Tel Aviv
- Életkor
- 18 év and over
- People
- 345 worldwide
- Run by
- Vastra Gotaland Region
See details and how to joinNCT05377047 - 1/2. fázisTaking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Haifa, Tel Aviv
- Életkor
- 18 év to 100 év
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - 2. fázisTaking peopleA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- Where
- Haifa
- Életkor
- 18 év and over
- People
- 37 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00 - No phaseTaking peopleEVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)
- Where
- Tel Aviv
- Életkor
- 21 év and over
- People
- 19
- Run by
- Tel-Aviv Sourasky Medical Center
See details and how to joinNCT07646171 - Korai 1. fázisTaking peopleA Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.
- Where
- Haifa
- Életkor
- 18 év to 85 év
- People
- 30
- Run by
- Rambam Health Care Campus
See details and how to joinNCT05753657 - 1/2. fázisTaking peoplePhase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer
- Where
- Jerusalem
- Életkor
- 18 év and over
- People
- 15
- Run by
- Shaare Zedek Medical Center
See details and how to joinNCT03591276